Role of CD47 in Hematological Malignancies.
Angiogenic Proteins
/ metabolism
Animals
Antibodies, Monoclonal, Humanized
/ therapeutic use
Antigens, Differentiation
/ metabolism
Antineoplastic Agents, Immunological
/ therapeutic use
CD47 Antigen
/ antagonists & inhibitors
Clinical Trials as Topic
Drug Delivery Systems
Drug Design
Drug Screening Assays, Antitumor
Hematologic Neoplasms
/ physiopathology
Humans
Integrins
/ metabolism
Leukemia
/ metabolism
Lymphoma, Non-Hodgkin
/ metabolism
Molecular Mimicry
Molecular Targeted Therapy
Myeloid Cells
/ metabolism
Neoplasm Metastasis
Neoplasm Proteins
/ antagonists & inhibitors
Oligopeptides
/ therapeutic use
Protein Binding
Protein Domains
Protein Interaction Mapping
Receptors, Immunologic
/ antagonists & inhibitors
Signal Transduction
/ physiology
CD47
Hematological cancers
Immunotherapy
Targeted therapy
Journal
Journal of hematology & oncology
ISSN: 1756-8722
Titre abrégé: J Hematol Oncol
Pays: England
ID NLM: 101468937
Informations de publication
Date de publication:
16 07 2020
16 07 2020
Historique:
received:
01
05
2020
accepted:
02
07
2020
entrez:
18
7
2020
pubmed:
18
7
2020
medline:
18
5
2021
Statut:
epublish
Résumé
CD47, or integrin-associated protein, is a cell surface ligand expressed in low levels by nearly all cells of the body. It plays an integral role in various immune responses as well as autoimmunity, by sending a potent "don't eat me" signal to prevent phagocytosis. A growing body of evidence demonstrates that CD47 is overexpressed in various hematological malignancies and its interaction with SIRPα on the phagocytic cells prevents phagocytosis of cancer cells. Additionally, it is expressed by different cell types in the tumor microenvironment and is required for establishing tumor metastasis. Overexpression of CD47 is thus often associated with poor clinical outcomes. CD47 has emerged as a potential therapeutic target and is being investigated in various preclinical studies as well as clinical trials to prove its safety and efficacy in treating hematological neoplasms. This review focuses on different therapeutic mechanisms to target CD47, either alone or in combination with other cell surface markers, and its pivotal role in impairing tumor growth and metastatic spread of various types of hematological malignancies.
Identifiants
pubmed: 32677994
doi: 10.1186/s13045-020-00930-1
pii: 10.1186/s13045-020-00930-1
pmc: PMC7364564
doi:
Substances chimiques
Angiogenic Proteins
0
Antibodies, Monoclonal, Humanized
0
Antigens, Differentiation
0
Antineoplastic Agents, Immunological
0
CD47 Antigen
0
CD47 protein, human
0
Integrins
0
Neoplasm Proteins
0
Oligopeptides
0
Receptors, Immunologic
0
SIRPA protein, human
0
Types de publication
Journal Article
Research Support, Non-U.S. Gov't
Review
Langues
eng
Sous-ensembles de citation
IM
Pagination
96Références
PLoS One. 2017 Oct 30;12(10):e0187262
pubmed: 29084248
Clin Cancer Res. 2016 Oct 15;22(20):5109-5119
pubmed: 27126995
J Biol Chem. 2004 Oct 8;279(41):42393-402
pubmed: 15292185
Br J Haematol. 2007 Sep;138(6):756-60
pubmed: 17760807
Pathol Res Pract. 2019 Feb;215(2):265-271
pubmed: 30466764
Cancer Sci. 2019 Jan;110(1):256-268
pubmed: 30460757
J Cell Biol. 2008 Mar 10;180(5):989-1003
pubmed: 18332220
Arthritis Res Ther. 2008;10(1):R4
pubmed: 18186923
Mol Cancer Ther. 2018 Aug;17(8):1739-1751
pubmed: 29743205
Science. 2013 Jul 5;341(6141):88-91
pubmed: 23722425
Nat Nanotechnol. 2019 Jan;14(1):89-97
pubmed: 30531990
J Biol Chem. 2003 Jun 27;278(26):23915-21
pubmed: 12690108
JCI Insight. 2017 Jan 12;2(1):e89140
pubmed: 28097229
J Biol Chem. 1994 Nov 25;269(47):29650-7
pubmed: 7525586
Clin Cancer Res. 2017 Feb 15;23(4):1068-1079
pubmed: 27856600
EBioMedicine. 2019 Apr;42:281-295
pubmed: 30878596
Mol Cell. 2008 Jul 25;31(2):266-77
pubmed: 18657508
Oncol Rep. 2012 Aug;28(2):465-72
pubmed: 22641236
Biochim Biophys Acta Gen Subj. 2017 Jun;1861(6):1597-1605
pubmed: 28161480
Adv Pharm Bull. 2017 Sep;7(3):339-348
pubmed: 29071215
Br J Pharmacol. 2012 Dec;167(7):1415-30
pubmed: 22774848
N Engl J Med. 2018 Nov 01;379(18):1711-1721
pubmed: 30380386
Blood Cancer J. 2017 Feb 24;7(2):e536
pubmed: 28234345
J Hematol Oncol. 2018 Mar 27;11(1):46
pubmed: 29580288
J Neurosci. 2004 Nov 3;24(44):9838-46
pubmed: 15525768
Exp Hematol. 2011 Apr;39(4):486-94
pubmed: 21211546
Transl Oncol. 2017 Aug;10(4):632-640
pubmed: 28668761
Transfus Apher Sci. 2002 Dec;27(3):233-8
pubmed: 12509218
Transfusion. 2019 Jul;59(7):2248-2254
pubmed: 31183877
Annu Rev Biochem. 2000;69:217-45
pubmed: 10966458
J Biol Chem. 2006 Sep 8;281(36):26069-80
pubmed: 16835222
J Oncol. 2019 Jun 4;2019:9852361
pubmed: 31275386
Mol Cancer. 2018 Jan 24;17(1):12
pubmed: 29368647
Cancer Sci. 2006 Sep;97(9):889-95
pubmed: 16776778
Proc Natl Acad Sci U S A. 2017 Dec 5;114(49):E10578-E10585
pubmed: 29158380
J Biol Chem. 2002 Nov 8;277(45):42859-66
pubmed: 12218055
J Biol Chem. 2005 Aug 19;280(33):29637-44
pubmed: 15917238
Blood. 2019 Oct 24;134(17):1430-1440
pubmed: 31383641
J Immunol. 2005 Dec 15;175(12):7781-7
pubmed: 16339510
ISRN Hematol. 2013;2013:614619
pubmed: 23401787
Oncotarget. 2017 Jul 4;8(27):44960-44975
pubmed: 28402953
Nat Med. 2019 Apr;25(4):612-619
pubmed: 30833751
MAbs. 2015;7(5):946-56
pubmed: 26083076
J Cell Sci. 1995 Nov;108 ( Pt 11):3419-25
pubmed: 8586654
Blood Adv. 2019 Apr 9;3(7):1145-1153
pubmed: 30962222
Cell. 2010 Sep 3;142(5):699-713
pubmed: 20813259
J Biochem. 2014 Jun;155(6):335-44
pubmed: 24627525
Front Oncol. 2020 Jan 22;9:1380
pubmed: 32038992
Blood. 2011 Nov 3;118(18):4890-901
pubmed: 21828138
PLoS One. 2010 Dec 22;5(12):e15686
pubmed: 21203512
Proc Natl Acad Sci U S A. 2016 May 10;113(19):E2646-54
pubmed: 27091975
PLoS One. 2015 Sep 21;10(9):e0137345
pubmed: 26390038
J Clin Invest. 2001 Jun;107(12):1499-500
pubmed: 11413154
Cell Oncol (Dordr). 2020 Feb;43(1):19-30
pubmed: 31485984
Mol Biol Cell. 1998 Apr;9(4):865-74
pubmed: 9529384
Science. 2016 Apr 8;352(6282):227-31
pubmed: 26966191
Mol Ther. 2013 Oct;21(10):1919-29
pubmed: 23774794
Antib Ther. 2018 Aug 28;1(2):37-42
pubmed: 34056543
PLoS One. 2018 Aug 22;13(8):e0201832
pubmed: 30133535
Blood. 2009 Oct 15;114(16):3413-21
pubmed: 19661269
Haematologica. 2019 Nov 28;105(12):2813-2823
pubmed: 33256380
Nat Med. 2019 Jul;25(7):1057-1063
pubmed: 31270504
Breast Cancer Res Treat. 2018 Nov;172(1):69-82
pubmed: 30056566
Cancers (Basel). 2020 Jan 28;12(2):
pubmed: 32012878
Chin J Cancer. 2017 Dec 16;36(1):94
pubmed: 29246182
Leuk Lymphoma. 2004 Jul;45(7):1319-27
pubmed: 15359629
MAbs. 2019 Aug/Sep;11(6):1036-1052
pubmed: 31257988
Eur J Cancer. 2014 Jul;50(10):1836-1846
pubmed: 24726056
Biochem Biophys Res Commun. 2006 May 19;343(4):1197-200
pubmed: 16580635
Nanomaterials (Basel). 2018 Nov 20;8(11):
pubmed: 30463284
J Immunol. 2003 Apr 1;170(7):3544-53
pubmed: 12646616
Cold Spring Harb Perspect Biol. 2011 Oct 01;3(10):a009712
pubmed: 21875984
J Biol Chem. 2015 May 15;290(20):12650-63
pubmed: 25837251
Cell. 2009 Jul 23;138(2):286-99
pubmed: 19632179
J Biol Chem. 2009 Jan 9;284(2):1116-25
pubmed: 19004835
Front Immunol. 2020 Jan 28;11:18
pubmed: 32082311
Cancer Sci. 2018 Aug;109(8):2349-2357
pubmed: 29873856
Eur J Cancer. 2017 May;76:100-109
pubmed: 28286286
Proc Natl Acad Sci U S A. 2012 Apr 24;109(17):6662-7
pubmed: 22451913
MAbs. 2018 Feb/Mar;10(2):315-324
pubmed: 29182441
J Cell Biol. 1990 Dec;111(6 Pt 1):2785-94
pubmed: 2277087
Int J Nanomedicine. 2017 Jul 24;12:5255-5269
pubmed: 28769562
Scand J Immunol. 2004 Jan;59(1):50-7
pubmed: 14723621
Cell. 2009 Jul 23;138(2):271-85
pubmed: 19632178
Blood. 2018 Jan 4;131(1):68-83
pubmed: 29118007
N Engl J Med. 2016 Nov 3;375(18):1767-1778
pubmed: 27806234
J Biol Chem. 2010 Dec 10;285(50):38923-32
pubmed: 20923780
Blood. 2002 Sep 1;100(5):1878-85
pubmed: 12176912
Leukemia. 2012 Dec;26(12):2538-45
pubmed: 22648449
Cancer Res. 2011 Feb 15;71(4):1374-84
pubmed: 21177380
PLoS One. 2009 Jul 28;4(7):e6371
pubmed: 19636412
Oncotarget. 2017 Feb 14;8(7):11284-11301
pubmed: 28061465